Millennium Management LLC increased its position in shares of Chimerix, Inc. (NASDAQ:CMRX) by 466.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 574,227 shares of the biopharmaceutical company’s stock after acquiring an additional 472,789 shares during the quarter. Millennium Management LLC owned about 0.67% of Chimerix worth $4,594,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Chimerix by 8.7% during the 2nd quarter. BlackRock Inc. now owns 4,957,038 shares of the biopharmaceutical company’s stock worth $39,655,000 after acquiring an additional 395,565 shares during the last quarter. Opaleye Management Inc. boosted its stake in Chimerix by 3.1% during the 2nd quarter. Opaleye Management Inc. now owns 4,630,000 shares of the biopharmaceutical company’s stock worth $37,040,000 after acquiring an additional 140,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in Chimerix by 3.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,588,079 shares of the biopharmaceutical company’s stock worth $28,705,000 after buying an additional 122,744 shares during the period. State Street Corp raised its holdings in Chimerix by 11.2% during the 2nd quarter. State Street Corp now owns 3,213,480 shares of the biopharmaceutical company’s stock worth $25,708,000 after buying an additional 322,518 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Chimerix by 4.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,258,399 shares of the biopharmaceutical company’s stock worth $18,066,000 after buying an additional 94,304 shares during the period. 52.97% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have commented on CMRX. Wedbush dropped their target price on shares of Chimerix from $15.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday. Zacks Investment Research upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, November 10th. Maxim Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Chimerix in a report on Friday, November 5th. Finally, HC Wainwright lifted their price objective on shares of Chimerix from $19.00 to $21.00 and gave the company a “buy” rating in a report on Monday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $16.54.
Shares of CMRX opened at $6.23 on Thursday. The company has a market cap of $541.15 million, a price-to-earnings ratio of -3.42 and a beta of 1.44. Chimerix, Inc. has a 1-year low of $3.38 and a 1-year high of $11.57. The company’s fifty day simple moving average is $5.99 and its 200 day simple moving average is $6.94.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.21). Chimerix had a negative net margin of 4,762.96% and a negative return on equity of 58.06%. During the same quarter in the previous year, the business earned ($0.18) earnings per share. On average, analysts predict that Chimerix, Inc. will post -0.97 earnings per share for the current year.
Chimerix Company Profile
Chimerix, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Further Reading: What is a stock buyback?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.